Proteasome mediates dopaminergic neuronal degeneration, and its inhibition causes alpha-synuclein inclusions. - Wikidata - wikimedia - TriplyDB

Proteasome mediates dopaminergic neuronal degeneration, and its inhibition causes alpha-synuclein inclusions.

Proteasome mediates dopaminergic neuronal degeneration, and its inhibition causes alpha-synuclein inclusions.

http://www.wikidata.org/entity/Q44691515

about

Regulation of autophagy by extracellular signal-regulated protein kinases during 1-methyl-4-phenylpyridinium-induced cell death Protein degradation pathways in Parkinson's disease: curse or blessing Clearance and phosphorylation of alpha-synuclein are inhibited in methionine sulfoxide reductase a null yeast cells.Nigral proteasome inhibition in mice leads to motor and non-motor deficits and increased expression of Ser129 phosphorylated α-synuclein Oxidative neurodegeneration is prevented by UCP0045037, an allosteric modulator for the reduced form of DJ-1, a wild-type of familial Parkinson's disease-linked PARK7.Adaptation to chronic MG132 reduces oxidative toxicity by a CuZnSOD-dependent mechanism beta-Synuclein reduces proteasomal inhibition by alpha-synuclein but not gamma-synuclein.Human DJ-1-specific transcriptional activation of tyrosine hydroxylase gene Neuroprotective effect of a new DJ-1-binding compound against neurodegeneration in Parkinson's disease and stroke model rats Decreased Phosphorylation and Increased Methionine Oxidation of α-Synuclein in the Methionine Sulfoxide Reductase A Knockout Mouse.Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopamine degeneration.Polyunsaturated fatty acids induce alpha-synuclein-related pathogenic changes in neuronal cells Inhibition of Protein Ubiquitination by Paraquat and 1-Methyl-4-Phenylpyridinium Impairs Ubiquitin-Dependent Protein Degradation Pathways.Cowden syndrome-related mutations in PTEN associate with enhanced proteasome activity.Molecular pathways and genetic aspects of Parkinson's disease: from bench to bedside.Parkinson's disease: genetic versus toxin-induced rodent models.Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps.Adaptation and sensitization to proteotoxic stress.MicroRNA expressing profiles in A53T mutant alpha-synuclein transgenic mice and Parkinsonian.Adaptive changes in autophagy after UPS impairment in Parkinson's disease.Metallothionein, Copper and Alpha-Synuclein in Alpha-Synucleinopathies.The Lewy body in Parkinson's disease and related neurodegenerative disorders.The Proteasome Inhibition Model of Parkinson's Disease.Astrocytes Surviving Severe Stress Can Still Protect Neighboring Neurons from Proteotoxic Injury.Commitment of 1-methyl-4-phenylpyrinidinium ion-induced neuronal cell death by proteasome-mediated degradation of p35 cyclin-dependent kinase 5 activator.DJ-1-binding compounds prevent oxidative stress-induced cell death and movement defect in Parkinson's disease model rats.Proteasome inhibition protects HT22 neuronal cells from oxidative glutamate toxicity.Ubiquitin-proteasome system impairment and MPTP-induced oxidative stress in the brain of C57BL/6 wild-type and GSTP knockout mice.Quality control system response to stochastic growth of amyloid fibrils.Accumulation of HtrA2/Omi in neuronal and glial inclusions in brains with alpha-synucleinopathies.6-Hydroxydopamine but not 1-methyl-4-phenylpyridinium abolishes alpha-synuclein anti-apoptotic phenotype by inhibiting its proteasomal degradation and by promoting its aggregation.Alpha-synuclein aggregation, Ubiquitin proteasome system impairment, and L-Dopa response in zinc-induced Parkinsonism: resemblance to sporadic Parkinson's disease.A Focus on the Beneficial Effects of Alpha Synuclein and a Re-appraisal of Synucleinopathies.Dexamethasone Inhibits Copper-Induced Alpha-Synuclein Aggregation by a Metallothionein-Dependent Mechanism.N-Acetyl-l-Cysteine Protects Astrocytes against Proteotoxicity without Recourse to Glutathione.Alpha-synuclein alters proteasome function, protein synthesis, and stationary phase viability.

P2860

Q24676936-230AAF2D-0C32-49D4-A67C-595E162DAD40 Q27026029-1173D4E9-D880-47CB-ADB0-50F84E8CE9A5 Q30379490-F4C68956-E51C-4DAE-8872-A373DFFF1A7D Q30633819-429F6A64-0B85-4749-8F57-D8F9B7D5F751 Q33596785-86DBBE89-1A1B-48A0-9FC2-DA7FE9D39609 Q33984045-67771739-04A4-4B0D-83F7-4ACF5F5FD192 Q34375304-C94B39DF-0646-4706-A946-07C21C4801CD Q34400824-6A935102-665C-4CC0-A5B8-9DAB5CF5B17E Q35121851-593526E8-F809-415D-879C-34D4DAEC6B20 Q35746279-F541B7B3-597D-42A5-A7CC-4E8A294B2EEB Q36088792-11E778C1-203C-432C-B4D6-D79BD726A0F8 Q36202906-161134EE-9556-4C8A-BC9D-AF47CD3855D0 Q36828581-41EFCCBF-4219-47F4-B41C-9479C6979BB3 Q36847305-C446B4D0-E92F-49B6-8EE5-E41964C0D534 Q37021321-B8F0C174-5E8D-4B43-BA65-86BE833B32A3 Q37086124-FB20621D-75B5-45AB-BCF5-6AFD803CE47E Q37376117-BB3E29D7-0736-4F4B-880D-C1AF5D137C44 Q37651678-2B82FB4D-D820-426A-9C1A-58810C8EA453 Q37702119-BA7E202C-5F23-496B-984D-38DD8F841598 Q37729051-CBB0CCE7-7CD8-4BBD-A209-1EDEB0FD8C19 Q37737068-57E6C337-8D38-47CA-B531-BB6245598736 Q38012653-B9C8545C-81B6-4F40-B60D-45CBED70E8C7 Q38996038-15C32897-50ED-41CE-9548-E04590CAFA29 Q39019452-A3A4632A-A4EA-4523-82C7-6C0185AC0E76 Q39819662-1A6B92BE-466F-441E-80EC-1CB0BCA99240 Q39997452-87035ACF-D2DC-4A1A-89A7-F0F9CDD678B8 Q40462899-2B997174-4836-413F-A1AA-41B6C30289DA Q43524396-29474E85-1F0F-41D0-A8DA-7B0B7C0B4D30 Q43745429-645CC83B-287E-4D97-B580-A97AD19005A6 Q46361020-EF8E0FEB-F79E-4B7A-8F7B-62365B2101C0 Q46933074-0BE6BA02-CDFC-46C6-9EE4-494C49334AF9 Q47338096-09AC3393-35FA-46AF-8063-167FB5F02936 Q47389795-B3D609A7-F03F-4A54-84AF-AFF0C378304C Q47611418-AF80778B-0256-4407-812F-7F188F458C5B Q47919698-09D9A5AC-210E-45BC-9318-B5EA8C8160B6 Q54660240-F15856F3-005A-44F1-9897-F4D388DDA5BE

P2860

Proteasome mediates dopaminergic neuronal degeneration, and its inhibition causes alpha-synuclein inclusions.

http://www.wikidata.org/entity/Q44691515

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Proteasome mediates dopaminerg ...... es alpha-synuclein inclusions.

@en

Proteasome mediates dopaminerg ...... es alpha-synuclein inclusions.

@nl

type

label

Proteasome mediates dopaminerg ...... es alpha-synuclein inclusions.

@en

Proteasome mediates dopaminerg ...... es alpha-synuclein inclusions.

@nl

prefLabel

Proteasome mediates dopaminerg ...... es alpha-synuclein inclusions.

@en

Proteasome mediates dopaminerg ...... es alpha-synuclein inclusions.

@nl

P1433

Q44691515-9D163732-064A-45D8-8389-A72749026F6C

P1476

Q44691515-CF04E90B-E56A-4896-9FDD-97ED8DC057B8

P2093

Q44691515-08A6E052-F6C7-49A0-A448-490144E912CB

Q44691515-5CE93B4E-E612-4045-BAD7-1D3580B8D7F9

Q44691515-604993B1-A854-4845-A51E-A0A39E7DAFB0

Q44691515-641CECDC-D5A5-48DA-8CDD-8784577AEA03

Q44691515-656C19B9-D1AF-4711-98F8-3988097D2EBE

Q44691515-7741BA4A-6624-49BA-AB7A-76A9558F6281

Q44691515-7E4352FA-13A7-47A4-A4FC-3B29492CAD91

Q44691515-A2B53D5C-DF8E-449E-B81F-EE6136317DFB

Q44691515-B160A114-D2C2-4B82-B81E-2AE03CB1C30E

Q44691515-B8258D47-6B97-46F2-922E-2629F2666BE8

P2860

Q44691515-044D7891-8D0A-40B6-B7E4-7A837AC61E9E

Q44691515-0CCD15CF-FFF2-4FEA-9BB4-96C49B2A65C4

Q44691515-12F66208-1CE6-4516-8ED5-D926BEF7D30F

Q44691515-1B8102B2-BB65-4621-BC93-763F06D6AECE

Q44691515-269A586D-49FD-4DC3-9548-EEBA6DE19B39

Q44691515-27146BC1-A500-4188-AEE5-68F91E8594EB

Q44691515-2E9016B6-A104-4BE8-8134-7FBB9C019A93

Q44691515-328BF3AC-A530-4C67-8664-02377B71BB5F

Q44691515-3439F861-89A4-4307-AF5C-A1953CD36ACC

Q44691515-353DDEF9-1041-4D7E-887D-5A7D73FBC656

P304

Q44691515-AA0D18B0-62EC-4BEE-962A-57C4ABCE17F1

P31

Q44691515-BECF0144-EF99-48CE-9B38-31048D563916

P356

Q44691515-B90E7248-9E89-435E-8A9E-05ED36BD79DB

P407

Q44691515-65E22168-07FC-40CE-8A2B-527DFF603089

P433

Q44691515-87EDDF85-2C1F-45F0-B589-B7D28358A44E

P478

Q44691515-DB293D54-8080-43B0-BA63-FA7087D8E6E9

P50

Q44691515-46667DF6-A7E2-4BEB-94AE-40DE26D1ED08

Q44691515-A8F8CBDC-AB5E-43E1-BF99-41D1EF8C4FBB

P577

Q44691515-FA7864D5-8A6F-40DE-96FB-8E54EC129C26

P698

Q44691515-FB508BC4-C420-4CAB-A2CF-2A749EE4BB59

P921

Q44691515-65ABCE09-121A-4A39-8146-9572A6F1087A

Q44691515-CF596C01-1FB9-4A3F-A8A3-2E43D3166DF8

P356

P1433

Journal of Biological Chemistry

P1476

Proteasome mediates dopaminerg ...... es alpha-synuclein inclusions.

@en

P2093

Akinori Akaike

http://www.w3.org/2001/XMLSchema#string

Hideyuki Sawada

http://www.w3.org/2001/XMLSchema#string

Hiroshi Shibasaki

http://www.w3.org/2001/XMLSchema#string

Kentarou Yamakawa

http://www.w3.org/2001/XMLSchema#string

Masatoshi Inden

http://www.w3.org/2001/XMLSchema#string

Miki Nakanishi

http://www.w3.org/2001/XMLSchema#string

Noriko Sakka

http://www.w3.org/2001/XMLSchema#string

Noriyuki Yamamoto

http://www.w3.org/2001/XMLSchema#string

Ryuichi Kohno

http://www.w3.org/2001/XMLSchema#string

Shun Shimohama

http://www.w3.org/2001/XMLSchema#string

P2860

Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis

Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase

Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1

TAK1 is a ubiquitin-dependent kinase of MKK and IKK

Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism

alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease

Lewy bodies and parkinsonism in families with parkin mutations

The PHD domain of MEKK1 acts as an E3 ubiquitin ligase and mediates ubiquitination and degradation of ERK1/2

Chronic systemic pesticide exposure reproduces features of Parkinson's disease

P304

10710-10719

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.M308434200

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

279

http://www.w3.org/2001/XMLSchema#string

P50

Tomoki Nakamizo

P577

2003-12-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14672949

http://www.w3.org/2001/XMLSchema#string

P921